Related Experiment Video

Updated: Feb 10, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K

Heart rate modulation in stable coronary artery disease without clinical heart failure: What we have already learned

Gian Piero Perna1, Fabio Vagnarelli2, Maurizio Volterrani3

  • 1Cardiology, Cardiovascular Department, "Ospedali Riuniti di Ancona", Ancona, Italy.

Contemporary Clinical Trials Communications
|May 9, 2018
PubMed

Insights

Ivabradine did not improve outcomes in stable coronary artery disease patients, especially those with severe angina. Interactions with other drugs may explain adverse events, suggesting heart rate is a risk marker, not a direct therapeutic target.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Elevated heart rate signifies cardiovascular risk in stable coronary artery disease (CAD).
  • Ivabradine selectively inhibits the sinus node "f" current, reducing heart rate without affecting blood pressure or contractility.

Purpose of the Study:

  • To evaluate the efficacy of ivabradine in improving outcomes in patients with stable CAD.
  • To investigate the interaction between ivabradine and patient subgroups, particularly those with and without angina.

Main Methods:

  • Analysis of the SIGNIFY trial data.
  • Subgroup analysis to identify interactions between ivabradine's effects and baseline characteristics like angina severity and concomitant medications.

Main Results:

  • Ivabradine addition to standard therapy did not improve outcomes in stable CAD patients.
  • A significant interaction was observed, with worse outcomes in patients with CCS class >II baseline, despite reduced angina.
  • Excluding patients with specific drug interactions (CYP3A4 inhibitors, certain calcium channel blockers) eliminated the harmful effect in severe angina subgroups.

Conclusions:

  • Heart rate is a marker of risk, not a direct risk factor or therapeutic target in stable CAD with preserved ejection fraction.
  • Ivabradine is indicated for angina treatment as an alternative/addition to beta-blockers.
  • Ivabradine should not be co-administered with CYP3A4 inhibitors or heart rate-lowering calcium channel blockers due to potential adverse interactions.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
634
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
411
Anatomy of the Heart01:27

Anatomy of the Heart

The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
120.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
993
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
947